<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161652</url>
  </required_header>
  <id_info>
    <org_study_id>LDRDME_247164</org_study_id>
    <nct_id>NCT03161652</nct_id>
  </id_info>
  <brief_title>Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema</brief_title>
  <official_title>Clinical Trial to Evaluate the Safety and Efficacy of Levosulpiride to Improve Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmen Clapp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Mexicano de Oftalmologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Autonoma de Queretaro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital Nuremberg &amp; Paracelsus Medical University Nuremberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Nacional Autonoma de Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial to evaluate the safety and
      efficacy of levosulpiride to improve retinal alterations due to diabetic macular edema and
      diabetic retinopathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic retinopathy (DR) and diabetic macular edema (DME) are the primary cause of
      irreversible blindness and visual impairment in working-age adults. Nearly 80% of patients
      with diabetes will experience some degree of DR and DME 15-20 years after diagnosis. Altered
      blood parameters (glucose, lipids, and pressure) influence disease development and
      progression; however, the combined values of these parameters account for only 10% of the
      risk of DR. Laser therapy is effective for preserving sight but is poor for reversing visual
      loss. Anti-angiogenic therapies are effective and less destructive but require frequent
      intravitreal delivery, which raises the risk of infection and ocular complications.
      Therefore, the prevention and treatment of DR and DME should include other modifiable
      factors. Data from preclinical studies support a protective role for the serum levels of the
      hormone prolactin. The trial investigates a new specific therapy for DR and DME based on
      elevating the circulating levels of prolactin with the prokynetic, dopamine D2 receptor
      blocker, levosulpiride. It is a prospective, randomized clinical study in patients with DR
      and DME in which ophthalmologic and health parameters evaluated before and after starting the
      study medication will determine the efficacy and safety of treatment.

      Patient registries: Patients are enrolled at the time of a routine health care service. The
      caregiver and patient together, in a standardized uniform manner for every patient, will
      collect the data. Data collection procedures are clearly described and include protocols,
      policies, and the formatted listing of all the data elements, their full definitions and
      validation rules. All personnel involved in data collection are qualified registry trained.
      The same physicians, laboratory technicians, and graduate students will evaluate and collect
      the data from all patients. An individual fully knowledgeable of all protocols, policies,
      procedures, and definitions in the registry will be designated as Accountable for Data
      Quality. This individual (coordinator) should ensure that all collected data are complete,
      accurate, and valid. Data logically inconsistent will be confronted to information in
      external database. Data collected on formatted paper forms are entered into a computer and
      electronic registries carefully reviewed by a third party to identify missing data, invalid
      or erroneous entries, and inconsistent data. Any data review activity and remediation efforts
      will be documented. Amelioration of data problems may include querying the personnel
      uploading the data, the coordinator, the interviewer, or the patient. The proposed sample
      size and study duration are the minimum required and are based on biological models of DR and
      on clinical experience evaluating primary data associated with the study. These parameters
      may have to be modified to accommodate the sample size required to obtain clinically
      important differences and their statistical evaluation, access to eligible patients, lack of
      adherence to therapy at specific calendar dates (holidays), etc. Statistical methods include
      those evaluating continuous and categorical variables, incidence and prevalence, the
      association between a risk factor and outcome, and the relative contribution of confounding
      factors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study investigates a medication causing hyperprolactinemia (levosulpiride) to treat diabetic retinopathy (DR) and diabetic macular edema (DME). Subjects are from four different populations, those with DME, non-proliferative DR, those undergoing vitrectomy due to proliferative DR, and those with DME plus standard intravitreal antiangiogenic therapy with ranibizumab. Immediately after baseline, each of the four groups are randomly split into two subgroups: one receiving placebo (sugar pill) and the other levosulpiride. Ophthalmologic and health outcomes between groups 1 and 2 (DME: placebo and levosulpiride), 3 and 4 (DR: placebo and levosulpiride), and 7 and 8 (DME plus ranibizumab: placebo and levosulpiride) evaluate the efficacy and safety of the study medication. Comparison of serum and vitreous prolactin levels between the groups undergoing vitrectomy (DR: placebo and levosulpiride) serve as a proof of principle that prolactin enters the eye to counteract disease progression.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Patients, care providers, and evaluators are blind to treatment allocation. This reduces the risk of bias in the measurement of outcomes, in the decision to modify or discontinue treatment, or to withdraw from trial or from analysis. The monitoring coordinator allocates the treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>5 minutes</time_frame>
    <description>Number of letters recognized in the Early Treatment Diabetic Retinopathy Study (ETDRS) chart test after correcting for any refractive error (myopia, hyperopia, or astigmatism)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal thickness</measure>
    <time_frame>Pupils are dilated (eye drops) for 10 to 15 minutes and optical coherence tomography (OCT) images recorded during 5 minutes.</time_frame>
    <description>Retinal thickness is evaluated by non-invasive optical coherence tomography (OCT) imaging via qualitative and quantitative analyses. For qualitative analyses, OCT images approaching the histological level of retinal morphology are interpreted based on normal and diseased features (hyper-reflective or hypo-reflective lesions, shadowing, and anatomical changes). Quantitative analysis evaluates retinal reflective signals and their correlation with retinal morphology by computer image-processing algorithms (retinal thickness map, volume, area, 1, 3, and 6 mm ETDRS circle diameters).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal hard exudates and hemorrhages</measure>
    <time_frame>Pupils are dilated (eye drops) for 10 to 15 minutes and fundus images recorded during 5 minutes</time_frame>
    <description>Number, size, and location of retinal hard exudates and hemorrhages evaluated by indirect ophthalmoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal microaneurisms, leakage area, cotton-wool spots, venous beading, microvascular and vascular abnormalities</measure>
    <time_frame>Pupils are dilated (eye drops) for 10 to 15 minutes and fundus images recorded before and at different times (0.5 to 5 minutes) after fluorescein injection.</time_frame>
    <description>Location, intensity, and source of above alterations evaluated by fundus fluorescein angiography imaging qualitative and quantitative analysis of hyper-fluorescent or hypo-fluorescent regions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prolactin serum levels</measure>
    <time_frame>1-2 minutes (duration of blood withdrawal)</time_frame>
    <description>ng/ml levels of prolactin quantified in serum samples using the IMMULITE 2000 XPi immunoassay system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prolactin vitreous levels</measure>
    <time_frame>2 minutes (duration of vitreous withdrawal during medically prescribed vitrectomy)</time_frame>
    <description>ng/ml levels of prolactin quantified in vitreous samples using the IMMULITE 2000 XPi immunoassay system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasoinhibin vitreous levels</measure>
    <time_frame>2 minutes (duration of vitreous withdrawal during medically prescribed vitrectomy)</time_frame>
    <description>Optical density values of vasoinhibins obtained by the immunoprecipitation-Western blot analysis of vitreous samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pyruvic glutamic transaminase (TGP) and thyroid stimulating hormone (TSH) serum levels</measure>
    <time_frame>1-2 minutes (duration of blood withdrawal)</time_frame>
    <description>U/L (TGP) and uU/mL (TSH) quantified in serum samples by the Bioclin Kinetic Transaminase ALT (TGP) Kit and the automatic quimioluminescent evaluator (TSH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glycated hemoglobin and creatinine serum levels</measure>
    <time_frame>1-2 minutes (duration of blood withdrawal)</time_frame>
    <description>Glycated hemoglobin (evaluated by boronate affinity chromatography) and creatinine (evaluated by the Jaffe reaction) levels are expressed as % and mg/dL, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>5 minutes</time_frame>
    <description>Systolic and diastolic values in mmHg</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>DME lactose pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with DME will be randomized to take a lactose pill (placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DME levosulpiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with DME will be randomized to take levosulpiride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DR lactose pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with non-proliferative DR will be randomized to take a lactose pill (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DR levosulpiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with non-proliferative DR will be randomized to take levosulpiride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DR, vitrectomy lactose pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take a lactose pill (placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DR, vitrectomy levosulpiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take levosulpiride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DME plus ranibizumab lactose pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take a lactose pill (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DME plus ranibizumab levosulpiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take levosulpiride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DME lactose pill</intervention_name>
    <description>Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.</description>
    <arm_group_label>DME lactose pill</arm_group_label>
    <other_name>placebo, sugar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DME levosulpiride</intervention_name>
    <description>Patients with DME will take levosulpiride (75 mg/day) orally TID for 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.</description>
    <arm_group_label>DME levosulpiride</arm_group_label>
    <other_name>dopamine D2 receptor blocker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DR lactose pill</intervention_name>
    <description>Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.</description>
    <arm_group_label>DR lactose pill</arm_group_label>
    <other_name>placebo, sugar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DR levosulpiride</intervention_name>
    <description>Patients with non-proliferative DR will take levosulpiride (75 mg/day) orally TIDfor 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.</description>
    <arm_group_label>DR levosulpiride</arm_group_label>
    <other_name>dopamine D2 receptor blocker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DR vitrectomy lactose pill</intervention_name>
    <description>Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.</description>
    <arm_group_label>DR, vitrectomy lactose pill</arm_group_label>
    <other_name>placebo, sugar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DR vitrectomy levosulpiride</intervention_name>
    <description>Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will take levosulpiride (75 mg/day) orally TID for one week. The last pill will be taken on the morning of the day vitrectomy is performed. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.</description>
    <arm_group_label>DR, vitrectomy levosulpiride</arm_group_label>
    <other_name>dopamine D2 receptor blocker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DME plus ranibizumab lactose pill</intervention_name>
    <description>Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks) will take a lactose pill (placebo) orally TID for 12 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.</description>
    <arm_group_label>DME plus ranibizumab lactose pill</arm_group_label>
    <other_name>placebo, sugar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DME plus ranibizumab levosulpiride</intervention_name>
    <description>Patients with DME with receive intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks) will take a levosulpiride (75 mg/day) orally TID for 12 weeks. The study medication is taken on top of standard therapy for diabetes and blood pressure control.</description>
    <arm_group_label>DME plus ranibizumab levosulpiride</arm_group_label>
    <other_name>dopamine D2 receptor blocker</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal or greater than 40 years but no older than 69 years

          -  Male and female subjects with mild and moderate diabetic macular edema (DME),
             non-proliferative diabetic retinopathy (DR), and with proliferative DR undergoing
             medically prescribed vitrectomy.

          -  Signing informed consent

          -  Without ocular complications: severe myopia (&gt; 6 diopters), ocular media opacity,
             retinal detachment, etc.

          -  Without previous ocular treatments: ocular surgeries, retinal laser photocoagulation,
             intravitreal administration of antiangiogenic agents (delivered &lt; 6 months before
             enrollment).

          -  Prolactin serum levels ≤ 20 ng/ml

          -  With normal or mild loss of kidney function (glomerular filtration rate &gt;60 ml/min)
             for groups with DME and DR without vitrectomy.

          -  With mild to severe loss of kidney function (glomerular filtration rate &gt;30 ml/min)
             for groups with DR undergoing vitrectomy.

          -  Without contraindications for the use of levosulpiride (Parkinson disease, epilepsy,
             breast cancer, alcoholism, hypokalemia).

          -  Without hyperprolactinemia inducing conditions: Pathologies (hypothyrodism, hepatic
             dysfunction, prolactinomas); Medication (antipsychotics, antidepressants, prokinetics,
             other)

        Exclusion Criteria:

          -  Not meeting inclusion criteria.

          -  Adverse and intolerable drug effects.

          -  Not complying with study medication

          -  Inability to continue in-hospital appointments.

          -  Missing outcome data

          -  Hesitation to continue with study medication

          -  Relocation to another state or country

          -  Voluntary withdrawal of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Clapp, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Universidad Nacional Autonoma de Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ludivina Robles Osorio, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Autonoma de Queretaro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renata Garcia Franco, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano de Oftalmologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jakob Triebel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Nuremberg General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmen Clapp, Ph.D.</last_name>
    <phone>52442 2381028</phone>
    <email>clapp@unam.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ludivina Robles Osorio, M.D., Ph.D.</last_name>
    <phone>52442 1921200</phone>
    <phone_ext>5301</phone_ext>
    <email>ludirobles7@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Mexicano de Oftalmologia (IMO)</name>
      <address>
        <city>Queretaro</city>
        <zip>76090</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Garcia Franco, M.D.</last_name>
      <phone>52442 229 0776</phone>
      <email>renatagarciafranco@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ellery Lopez Star, M.D.</last_name>
      <phone>52442 229 0776</phone>
      <email>ellerylopezstar@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Renata Garcia Franco, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ximena Mira Lorenzo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulina Ramirez Neira, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos D Nuñez Amaro, B.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://personal.inb.unam.mx/clapp/</url>
    <description>Carmen Clapp's research web page</description>
  </link>
  <link>
    <url>http://www.inb.unam.mx/inweb3/instituto/direccion1_1.html</url>
    <description>Instituto de Neurobiologia, Universidad Nacional Autonoma de Mexico web page</description>
  </link>
  <link>
    <url>http://www.iapb.org/member/instituto-mexicano-de-oftalmologia-imo</url>
    <description>Instituto Mexicano de Oftalmologia web page</description>
  </link>
  <reference>
    <citation>Aranda J, Rivera JC, Jeziorski MC, Riesgo-Escovar J, Nava G, López-Barrera F, Quiróz-Mercado H, Berger P, Martínez de la Escalera G, Clapp C. Prolactins are natural inhibitors of angiogenesis in the retina. Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2947-53.</citation>
    <PMID>16043870</PMID>
  </reference>
  <reference>
    <citation>García C, Aranda J, Arnold E, Thébault S, Macotela Y, López-Casillas F, Mendoza V, Quiroz-Mercado H, Hernández-Montiel HL, Lin SH, de la Escalera GM, Clapp C. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J Clin Invest. 2008 Jun;118(6):2291-300. doi: 10.1172/JCI34508.</citation>
    <PMID>18497878</PMID>
  </reference>
  <reference>
    <citation>Clapp C, Thebault S, Arnold E, García C, Rivera JC, de la Escalera GM. Vasoinhibins: novel inhibitors of ocular angiogenesis. Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E772-8. doi: 10.1152/ajpendo.90358.2008. Epub 2008 Jun 10. Review.</citation>
    <PMID>18544641</PMID>
  </reference>
  <reference>
    <citation>Arnold E, Rivera JC, Thebault S, Moreno-Páramo D, Quiroz-Mercado H, Quintanar-Stéphano A, Binart N, Martínez de la Escalera G, Clapp C. High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes. 2010 Dec;59(12):3192-7. doi: 10.2337/db10-0873. Epub 2010 Sep 7.</citation>
    <PMID>20823101</PMID>
  </reference>
  <reference>
    <citation>Triebel J, Macotela Y, de la Escalera GM, Clapp C. Prolactin and vasoinhibins: Endogenous players in diabetic retinopathy. IUBMB Life. 2011 Oct;63(10):806-10. doi: 10.1002/iub.518. Epub 2011 Sep 13. Review.</citation>
    <PMID>21913303</PMID>
  </reference>
  <reference>
    <citation>Ramírez M, Wu Z, Moreno-Carranza B, Jeziorski MC, Arnold E, Díaz-Lezama N, Martínez de la Escalera G, Colosi P, Clapp C. Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability. Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):8944-50. doi: 10.1167/iovs.11-8190.</citation>
    <PMID>22003113</PMID>
  </reference>
  <reference>
    <citation>Arnold E, Thebault S, Baeza-Cruz G, Arredondo Zamarripa D, Adán N, Quintanar-Stéphano A, Condés-Lara M, Rojas-Piloni G, Binart N, Martínez de la Escalera G, Clapp C. The hormone prolactin is a novel, endogenous trophic factor able to regulate reactive glia and to limit retinal degeneration. J Neurosci. 2014 Jan 29;34(5):1868-78. doi: 10.1523/JNEUROSCI.2452-13.2014.</citation>
    <PMID>24478366</PMID>
  </reference>
  <reference>
    <citation>Arredondo Zamarripa D, Díaz-Lezama N, Meléndez García R, Chávez Balderas J, Adán N, Ledesma-Colunga MG, Arnold E, Clapp C, Thebault S. Vasoinhibins regulate the inner and outer blood-retinal barrier and limit retinal oxidative stress. Front Cell Neurosci. 2014 Oct 20;8:333. doi: 10.3389/fncel.2014.00333. eCollection 2014.</citation>
    <PMID>25368550</PMID>
  </reference>
  <reference>
    <citation>Díaz-Lezama N, Wu Z, Adán-Castro E, Arnold E, Vázquez-Membrillo M, Arredondo-Zamarripa D, Ledesma-Colunga MG, Moreno-Carranza B, Martinez de la Escalera G, Colosi P, Clapp C. Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1. Lab Invest. 2016 Mar;96(3):283-95. doi: 10.1038/labinvest.2015.135. Epub 2015 Nov 16.</citation>
    <PMID>26568297</PMID>
  </reference>
  <reference>
    <citation>Meléndez García R, Arredondo Zamarripa D, Arnold E, Ruiz-Herrera X, Noguez Imm R, Baeza Cruz G, Adán N, Binart N, Riesgo-Escovar J, Goffin V, Ordaz B, Peña-Ortega F, Martínez-Torres A, Clapp C, Thebault S. Prolactin protects retinal pigment epithelium by inhibiting sirtuin 2-dependent cell death. EBioMedicine. 2016 May;7:35-49. doi: 10.1016/j.ebiom.2016.03.048. Epub 2016 Apr 20.</citation>
    <PMID>27322457</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Nacional Autonoma de Mexico</investigator_affiliation>
    <investigator_full_name>Carmen Clapp</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>diabetic retinopathy</keyword>
  <keyword>blindness</keyword>
  <keyword>eye</keyword>
  <keyword>macular edema</keyword>
  <keyword>prolactin</keyword>
  <keyword>dopamine antagonists</keyword>
  <keyword>peptide hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is yet undecided whether case reports will be published in medical journals throughout the course of the study. No identifier linking participants in the study to research records will be made public or reported.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

